Advancing Therapeutic and Vaccine Proteins: Switching from Recombinant to Ribosomal Delivery—A Humanitarian Cause
Sarfaraz K Niazi, Matthias Magoola, Lasse Lindahl · 2024
Read Advancing Therapeutic and Vaccine Proteins: Switching from Recombinant to Ribosomal Delivery—A Humanitarian Cause by Sarfaraz K Niazi, Matthias Magoola, Lasse Lindahl (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11641290.txt.
Description
Modern protein drugs heal millions, yet making them in cell factories is slow and dear, locking out most of humanity. Sarfaraz Niazi and co-authors argue in 2024 for switching delivery to the body's own ribosomes: send messenger RNA, and the patient's cells brew the protein on site, as COVID-19 vaccines proved possible. The goods cost a small fraction of the factory route.
Open questions remain about how regulators should class these products, drug, biologic, or gene therapy, and how copies would enter as generics or new biologics. Either way, the authors frame the switch as a humanitarian cause for the 6.5 billion people priced out today.
Catalog record
| CREATOR | Sarfaraz K Niazi, Matthias Magoola, Lasse Lindahl |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |